MOUD Buprenorphine Sublocade denied as non-formulary by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for moud buprenorphine sublocade are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denies Sublocade as Non-Formulary — and Your Path to Coverage

A non-formulary denial means Sublocade (extended-release injectable buprenorphine) is not listed on UnitedHealthcare's preferred drug list for your specific plan, or is listed at a tier that requires additional authorization. This is a coverage structure decision, not a determination that the drug is unsafe or clinically inappropriate. Non-formulary status does not end your options — you have both a formulary exception pathway and a full federal appeal process.

## Why This Denial Is Appealable

The ACA requires most non-grandfathered plans to offer an exceptions process for non-formulary drugs when a covered drug on the formulary is contraindicated, expected to be less effective, or expected to cause adverse effects for that patient. OUD treatment with extended-release injectable buprenorphine has specific clinical properties — particularly consistent plasma levels and elimination of daily dosing — that are not replicated by every formulary alternative. A prescriber attestation to that effect is the foundation of a non-formulary exception.

Federal parity law (MHPAEA) is also relevant: if the plan grants formulary exceptions for medications treating other chronic medical conditions with less restrictive documentation requirements, that asymmetry is a parity violation.

## Your Federal Appeal Rights

• Formulary exception / prior authorization: Before or alongside a formal appeal, request a formulary exception. Your prescriber submits documentation that the formulary alternative(s) are clinically inappropriate for this patient.
• Internal appeal (ACA §2719 / ERISA §503): If the exception is denied, you have the right to a full-and-fair internal appeal. File within the timeframe on your denial notice.
• External review: After internal exhaustion (or if the plan misses its deadline), you may request independent external review — typically within four months of the internal denial notice under ACA §2719 rules.
• Expedited process: Available if the standard timeline poses a risk to the patient's health or safety.

## Concrete Appeal Steps

1. Obtain the denial letter and confirm the exact reason (non-formulary vs. tier placement requiring PA). 2. Identify the formulary alternative(s) UHC would cover. Pull their names and have the prescriber evaluate why each is clinically inferior for this patient. 3. Request UHC's published coverage/formulary exception policy for Sublocade. 4. Have the prescriber complete the formulary exception request, documenting clinical distinction of the injectable formulation. 5. If denied, file the formal internal appeal with the full documentation package.

## Documentation to Gather

• Diagnosis confirmation: DSM-5 moderate-to-severe OUD diagnosis in the record.
• Formulary alternative evaluation: For each drug UHC lists as the preferred alternative, a prescriber note explaining why that alternative is contraindicated, less effective, or clinically inappropriate for this specific patient. You do not need to allege a specific interaction as fact — the prescriber documents their clinical judgment.
• Prior treatment history: Any prior trials of formulary alternatives with dates and documented outcomes.
• Prescriber medical-necessity letter: Explaining why the injectable extended-release formulation is clinically necessary, referencing the FDA-approved label for eligibility criteria and SAMHSA/ASAM guidelines by organization name.
• Criteria-mapping table: UHC's exception criteria in one column; the responsive chart documentation in the other.

## Criteria-Mapping Structure

Non-formulary exception decisions typically hinge on two or three discrete criteria (most commonly: formulary alternative tried and failed, contraindicated, or clinically inferior for documented reasons). Map each criterion explicitly. An unanswered criterion is the most common reason a well-supported exception is still denied on the first submission.